Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat
January 28, 2013 by MassDevice staff
Ocular Therapeutix raises another $24 million for its punctum plugs to treat eye diseases such as glaucoma.
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
Navigation
NEWS
Weight loss: GI Dynamics' U.S. clinical trial taxes its coffers
Weight-loss devices maker GI Dynamics tells investors today that the company may seek new funding as...
Medtronic touts European win for Export Advance aspiration catheter
Medical device giant Medtronic announces CE Mark approval in the European Union and imminent...
Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat
Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its...
Can the FDA keep its user fee promises amid sequester?
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
